RE: Getting interesting28 Nov 2016 10:12
Agreed, but don't underestimate the true potential here. If either Pisces2 or the RP trial shows positive results, as I believe they will, it completely ignites the stem-cell therapy platform. Japan in particular is watching the stroke trial intensely as it has already indicated that it would 'fast-track' SCT from phase1/2 to early use. America is seen to be taking a similar stance. A lot of the risk is offset by cash till end 2018 and having multiple trials in place for different conditions. Bear in mind also, that the target conditions - stroke, RP and glioma - have huge unmet needs in the way of drug therapy. Reneuron is creating the pathway for SCT and I expect volume to increase markedly this week as the Pisces2 results are released next week. The possibilities for interventions in stroke, Alzheimers, RP, cancers and a variety of other problem conditions could open and that makes RENE a very interesting niche company IMO.